|
|
|
|
|
|
|
|
|
|
Robbing Peter to Pay Paul: Financing Clinical Trial Follow-Up
David M. Dilts, Oregon Health and Science University, Knight Cancer Institute, Portland, OR
See accompanying article doi: 10.1200/JCO.2011.37.2698
"....With this total-cost knowledge, sites should be able to
do a better job of selecting trials that match their scientific interests,
their patient populations, and their fiscal necessities, and stop cross subsidizing old trials with new trials—in essence, stop robbing Peter to
pay Paul."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.